The Gut Science Behind Modern Weight Loss

Professor Arne Astrup: I am excited to be part of Azento Health, as their approach for supporting GLP-1 patients is unique. Their microbiome-focused solutions represent a significant contribution to patient health and well-being.

Since I together with Professor Jens Holst in 1996 discovered GLP-1 as being a satiety hormone in humans, I have been working with GLP-1s. I look forward to contributing to Azento Health’s mission.

• Addressing gut microbiome imbalances that are common in obesity and may worsen with rapid weight loss.
• Reducing gastrointestinal side effects and improving overall gut health to enhance treatment success.
• Enabling better metabolic outcomes, weight maintenance, and long-term health through nutritional and microbiome-focused solutions.